The growing incidence of tumors, diabetes, and autoimmune diseases has created a huge need for more efficient treatment choices, which drives the growth of the market.
What are Biotherapeutics?
A biotherapeutic is a healthcare product manufactured or extracted from biological sources. Composed of larger and more multifaceted molecules than chemically-synthesized drugs, biotherapeutic medicines need sophisticated manufacturing and control processes. Technological development in the sector of biotherapeutics continues to offer opportunities to manage an increasing number of diseases. Biotherapeutics is a significantly increasing field of pharmaceuticals that is helping to prevent and treat serious illnesses such as cancer. Biotherapeutics is a rapidly advancing field within the pharmaceutical manufacturing. Biotherapeutics differ from classic therapeutics as, rather than being chemically synthesized, biotherapeutic drugs have their active substance created from or extracted from a biological source.
Global Market Growth
The global biotherapeutics market size was estimated at USD 485.72 billion in 2025 and is predicted to increase from USD 533.51 billion in 2026 to approximately USD 1241.63 billion by 2035, expanding at a CAGR of 9.84% from 2026 to 2035.
Gene Therapy Clinical Trial in Various Regions
| Region |
Percentage |
| United States |
52.7% |
| China |
16.7% |
| United Kingdom |
6.3% |
| Germany |
2.9% |
| France |
1.7% |
| Japan |
1.4% |
| Switzerland |
1.3% |
Integration of AI-driven Technology in Biotherapeutics:
Biotherapeutics is experiencing a significant transformation by incorporating AI and generative biology, moving away from trial-and-error approaches to data-driven, predictive workflows. This progress emphasizes how AI and generative methods accelerate drug discovery and highlights the rise of new therapeutic modalities such as CAR T-cell therapies and RNA-based treatments. AI is playing a crucial role in advancing antibody design and target identification. Additionally, generative models like transformers and diffusion models are now employed to develop new, functional therapeutic proteins.
Market Segmentation Overview
- By product type, the monoclonal antibodies segment contributed the largest U.S. biotherapeutics market share of 41% in 2025. Monoclonal antibodies (mAbs) transformed oncology medicine by providing highly targeted and effective therapies that specifically attack cancer cells. mAbs have their high selectivity, specificities, and affinities that are optimized towards nearly every biomolecule of interest.
- By source type, the mammalian cells segment accounted for the largest market share at 63%, as mammalian expression systems are usually the favoured platform for the production of biopharmaceuticals, since these cell lines produce large, multifaceted proteins with post-translational modifications similar to those found in humans.
- By application, the oncology segment contributed the largest U.S. biotherapeutics market share of 36%, as biotherapeutics make cancer cells easier for the immune system to find. Biological therapy targets the tumor cells, turning on or off cell signals that support cancer cells hiding from the immune system. Biotherapeutics are engineered to target particular cancer antigens or molecular ways.
- By route of administration, the intravenous segment contributed the largest market share of 48%, as intravenous medicines deliver an immediate, rapidly-acting therapeutic outcome, which is significant in developing situations, like cardiac arrest or narcotic overdose. They are beneficial to manage pain and nausea by rapidly achieving therapeutic levels, and they are more reliably and completely absorbed as compared with therapeutics given by other routes of injection.
Top Companies in the U.S. Biotherapeutics Market
The five organizations in this market dominate the U.S. biotherapeutics market. Meanwhile, Amgen Inc., a pioneer in human therapeutics, focuses on inflammation, oncology, and bone health. Roche Holding AG, leading in cancer and immunology with specialized antibody production. Pfizer Inc. has a broad portfolio, including vaccines, oncology, and gene therapy. Novartis AG, innovative medicine, cell and gene therapies.
Segments Covered in the Report
By Product Type
- Monoclonal Antibodies
- Human Monoclonal Antibodies
- Humanised Monoclonal Antibodies
- Chimeric Monoclonal Antibodies
- Bispecific Antibodies
- Recombinant Proteins
- Insulin
- Erythropoietin
- Growth Hormones
- Interferons
- Coagulation Factors
- Vaccines
- Recombinant Vaccines
- Conjugate Vaccines
- mRNA Vaccines
- Viral Vector Vaccines
- Cell & Gene Therapy
- CAR-T Cell Therapy
- Stem Cell Therapy
- Gene Editing Therapy
- Viral Gene Therapy
- Biosimilars
- Oncology Biosimilars
- Autoimmune Biosimilars
- Insulin Biosimilars
- Growth Hormone Biosimilars
- Others
- Antisense Therapies
- RNA Therapeutics
- Peptide Therapeutics
By Source
- Mammalian Cells
- CHO Cells
- NSO Cells
- BHK Cells
- Microbial Cells
- Plant-Based Systems
- Transgenic Animals
By Application
- Oncology
- Solid Tumours
- Haematological Malignancies
- Autoimmune & Inflammatory Diseases
- Rheumatoid Arthritis
- Psoriasis
- Crohn’s Disease
- Infectious Diseases
- Viral Diseases
- Bacterial Diseases
- Metabolic Disorders
- Diabetes
- Rare Metabolic Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Rare Diseases
By Route of Administration
- Intravenous
- Subcutaneous
- Intramuscular
- Oral
- Others
By Manufacturing Type
- In-house Manufacturing
- Contract Manufacturing
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Speciality Pharmacies
By End User
- Hospitals
- Speciality Clinics
- Research Institutes
- Homecare Settings
